US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Truist raises Axsome Therapeutics stock target to $190 on Symbravo approval
Truist Securities adjusted their financial outlook for Axsome Therapeutics (NASDAQ:AXSM), increasing the price target to $190 from the previous $180 while maintaining a Buy rating on the company's shares.
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion Complex (MoSEIC) rapid-absorption technology. It combines with rizatriptan, a 5-HT1B/1D agonist, which was previously sold by Merck as Maxalt before it went generic. Triptans are a first-line class of treatments for migraine.
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Buy Rating for Axsome Therapeutics Driven by Symbravo Approval and Strategic Market Approach
Analyst Ami Fadia of Needham maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of
Axsome Shares Up Post Market After Hitting Record High on FDA Approval
Shares of Axsome Therapeutics rose post-market after the company received approval for Symbravo from the Food and Drug Administration. Symbravo, for the acute treatment of migraine with or without aura in adult patients,
FDA approves Axsome's novel migraine treatment SYMBRAVO
This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient outcomes with its portfolio of FDA-approved and late-stage development programs.
Axsome Therapeutics’ Promising Market Potential Following FDA Approval of Symbravo for Acute Migraine
Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of
Axsome Therapeutics' SWOT analysis: CNS drug developer's stock poised for growth
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...
Axsome Therapeutics price target raised to $137 from $122 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $137 from $122 and keeps an Outperform rating ...
Axsome Therapeutics (NASDAQ:AXSM) Given Outperform Rating at Royal Bank of Canada
Royal Bank of Canada reaffirmed their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report published on Wednesday morning,Benzinga reports. They currently have a ...
Seeking Alpha3d
AXSM Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...
Axsome Therapeutics price target raised to $190 from $180 at Truist
Truist analyst Joon Lee raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares.
Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC Wainwright
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued ...
RBC Capital lifts Axsome stock target to $143, sees launch potential
RBC Capital Markets analyst Leonid Timashev increased the price target for Axsome Therapeutics (NASDAQ:AXSM) to $143 from $139, while keeping an Outperform rating on the stock. According to ...